Lb Pharmaceuticals (LBRX) Assets Average (2025 - 2026)
Lb Pharmaceuticals (LBRX) recorded quarterly Assets Average of $353.2 million in Q1 2026, up 11.48% quarter-over-quarter from $316.8 million in Q4 2025.
Lb Pharmaceuticals (LBRX) Assets Average (2025 - 2026) Analysis & Trends
Lb Pharmaceuticals' Assets Average history runs 2 years deep, the most recent figure standing at $353.2 million for Q1 2026.
- In Q1 2026, Assets Average changed N/A year-over-year to $353.2 million; the TTM figure through Mar 2026 stood at $353.2 million (changed N/A YoY), while the FY2025 annual figure was $173.2 million, changed N/A from the prior year.
- Assets Average was $353.2 million for Q1 2026 at Lb Pharmaceuticals, up from $316.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $353.2 million in Q1 2026 to a low of $316.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 26.03 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 40.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 660.38 Mn |
| 10 | Lb Pharmaceuticals | 843.30 Mn | 843.30 Mn | - | 353.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 353.21 Mn |
| Dec 31, 2025 | 316.84 Mn |